Ind-Swift Ltd
Incorporated in 1986, Ind-Swift Ltd deals in manufacturing and exporting of pharmaceutical products
- Market Cap ₹ 90.1 Cr.
- Current Price ₹ 16.6
- High / Low ₹ 34.7 / 12.0
- Stock P/E 11.5
- Book Value ₹ -74.3
- Dividend Yield 0.00 %
- ROCE 11.9 %
- ROE %
- Face Value ₹ 2.00
Pros
Cons
- Company has low interest coverage ratio.
- Contingent liabilities of Rs.72.4 Cr.
- Earnings include an other income of Rs.328 Cr.
- Working capital days have increased from -13.2 days to 64.5 days
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|
| 308 | 263 | 270 | 398 | 411 | 502 | 515 | |
| 465 | 328 | 262 | 352 | 369 | 448 | 492 | |
| Operating Profit | -157 | -65 | 8 | 45 | 42 | 54 | 23 |
| OPM % | -51% | -25% | 3% | 11% | 10% | 11% | 4% |
| 13 | -246 | -20 | 24 | 72 | 53 | 328 | |
| Interest | 19 | 16 | 7 | 57 | 60 | 63 | 39 |
| Depreciation | 36 | 36 | 35 | 32 | 29 | 27 | 24 |
| Profit before tax | -200 | -363 | -53 | -20 | 26 | 16 | 288 |
| Tax % | 0% | 0% | 1% | 2% | 0% | 14% | 2% |
| -214 | -373 | -50 | -20 | 26 | 14 | 283 | |
| EPS in Rs | -42.42 | -68.81 | -9.31 | -3.70 | 4.81 | 2.63 | 52.33 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 9% |
| TTM: | 3% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 33% |
| TTM: | 132% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 14% |
| 5 Years: | 47% |
| 3 Years: | 18% |
| 1 Year: | -23% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | % |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|
| Equity Capital | 10 | 11 | 11 | 11 | 11 | 11 | 11 |
| Reserves | -270 | -641 | -688 | -731 | -716 | -702 | -413 |
| 1,061 | 1,062 | 1,055 | 1,036 | 993 | 1,014 | 874 | |
| 254 | 232 | 237 | 316 | 361 | 331 | 257 | |
| Total Liabilities | 1,055 | 665 | 615 | 632 | 649 | 654 | 728 |
| 374 | 342 | 311 | 236 | 216 | 184 | 243 | |
| CWIP | 4 | 2 | 0 | 9 | 30 | 51 | 0 |
| Investments | 39 | 39 | 46 | 64 | 54 | 1 | 6 |
| 638 | 281 | 258 | 323 | 349 | 418 | 480 | |
| Total Assets | 1,055 | 665 | 615 | 632 | 649 | 654 | 728 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|
| -119 | -2 | 7 | 50 | 73 | 15 | 16 | |
| 10 | 4 | -6 | -18 | -29 | 77 | 3 | |
| 110 | -11 | -6 | -45 | -47 | -42 | -13 | |
| Net Cash Flow | 0 | -8 | -5 | -13 | -3 | 50 | 6 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|
| Debtor Days | 451 | 151 | 113 | 83 | 93 | 111 | 112 |
| Inventory Days | 151 | 86 | 108 | 120 | 150 | 83 | 150 |
| Days Payable | 290 | 356 | 394 | 353 | 393 | 262 | 143 |
| Cash Conversion Cycle | 311 | -119 | -173 | -149 | -150 | -68 | 120 |
| Working Capital Days | 409 | -37 | -57 | -69 | -77 | -27 | 64 |
| ROCE % | -14% | -4% | 8% | 13% | 12% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Resignation of Company Secretary / Compliance Officer
22 Jul - Company Secretary Puneet Khurana resigns effective July 22, 2025, to pursue other opportunities.
-
Announcement under Regulation 30 (LODR)-Scheme of Arrangement
17 Jul - NCLT approves amalgamation scheme of Ind-Swift Limited with Ind-Swift Laboratories, effective post filing.
- Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 8 Jul
- Closure of Trading Window 30 Jun
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
27 Jun - Newspaper Publication of the financial Results for the Quarter and Year Ended 31.03.2025
Annual reports
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
-
Financial Year 2009
from bse
Business Overview:[1]
Company has expertise in finished goods dosage, Active Pharmaceutical Ingredients (API’s) and herbal products. Company also diversified into multiple fields viz., Infrastructure, Printing, Packaging & Stationary, Education, and Media Publication with its every unit as an independent profit earning center